PURA – Puration $0.35 Target Price Recommendation Confirmed by CBD Beverage Industry Survey Final Results

DALLAS, Oct. 10, 2019 /PRNewswire/ — Puration, Inc. (PURA) today announced the publication of the final results from the Goldman Small Cap Research CBD beverage industry survey (see link below) conducted in conjunction with the PURA’s initiative to launch new CBD Infused beer, coffee and tea beverages. Goldman summarizes the results with a confirmation of the $0.35 Price target for the shares of PURA and a Speculative Buy recommendation issued on September 25, 2019 (see link below to Sep 25 Analyst Report).

$0.35 price target.”

TranquiliTeaCBD and a new coffee infused with CBD in addition to including a progress update on the company’s progress toward its 2019 $4 million sales milestone.” data-reactid=”16″>Tomorrow, On Friday, October 11, 2019, PURA will publish an update on the launch of TranquiliTeaCBD and a new coffee infused with CBD in addition to including a progress update on the company’s progress toward its 2019 $4 million sales milestone.

European distribution agreement anticipated to generate $4 million annually with a first shipment scheduled later this month.” data-reactid=”17″>PURA has reported over $1 million in CBD beverage sales in the first six months of 2019 after reporting approximately $1 million in sales for all of 2018. On top of its ongoing sales, PURA has signed a new European distribution agreement anticipated to generate $4 million annually with a first shipment scheduled later this month.

To see the full final CBD Beverage industry survey results, follow the link below:

CBD Beverage Industry Results – October 10, 2019” data-reactid=”19″>CBD Beverage Industry Results – October 10, 2019

To see the original full Analyst Report, follow the link below:

PURAITON, Inc. Research Analyst Report – September 25, 2019” data-reactid=”21″>PURAITON, Inc. Research Analyst Report – September 25, 2019

http://www.purationinc.com” data-reactid=”22″>For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

info@aciconglomerated.com
+1-(800)-861-1350” data-reactid=”25″>Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
+1-(800)-861-1350